322 related articles for article (PubMed ID: 33660299)
1. High CD8
Koemans WJ; van Dieren JM; van den Berg JG; Meijer GA; Snaebjornsson P; Chalabi M; Lecot F; Riedl R; Krijgsman O; Hofland I; Broeks A; Voncken FEM; Peppelenbosch MP; Sosef MN; van Sandick JW; Kodach LL
Histopathology; 2021 Aug; 79(2):238-251. PubMed ID: 33660299
[TBL] [Abstract][Full Text] [Related]
2. Tumor-immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas.
Soeratram TT; Creemers A; Meijer SL; de Boer OJ; Vos W; Hooijer GK; van Berge Henegouwen MI; Hulshof MC; Bergman JJ; Lei M; Bijlsma MF; Ylstra B; van Grieken NC; van Laarhoven HW
J Pathol; 2022 Mar; 256(3):282-296. PubMed ID: 34743329
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 expression, CD8+ and CD4+ lymphocyte rate are predictive of pathological complete response after neoadjuvant chemoradiotherapy for squamous cell cancer of the thoracic esophagus.
Fassan M; Cavallin F; Guzzardo V; Kotsafti A; Scarpa M; Cagol M; Chiarion-Sileni V; Maria Saadeh L; Alfieri R; Castagliuolo I; Rugge M; Castoro C; Scarpa M
Cancer Med; 2019 Oct; 8(13):6036-6048. PubMed ID: 31429521
[TBL] [Abstract][Full Text] [Related]
4. Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
Noble F; Mellows T; McCormick Matthews LH; Bateman AC; Harris S; Underwood TJ; Byrne JP; Bailey IS; Sharland DM; Kelly JJ; Primrose JN; Sahota SS; Bateman AR; Thomas GJ; Ottensmeier CH
Cancer Immunol Immunother; 2016 Jun; 65(6):651-62. PubMed ID: 27020682
[TBL] [Abstract][Full Text] [Related]
5. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy.
Chen TW; Huang KC; Chiang SF; Chen WT; Ke TW; Chao KSC
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1043-1053. PubMed ID: 30874889
[TBL] [Abstract][Full Text] [Related]
7. Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer.
Teng F; Meng X; Kong L; Mu D; Zhu H; Liu S; Zhang J; Yu J
Transl Res; 2015 Dec; 166(6):721-732.e1. PubMed ID: 26209749
[TBL] [Abstract][Full Text] [Related]
8. The oesophageal adenocarcinoma tumour immune microenvironment dictates outcomes with different modalities of neoadjuvant therapy - results from the AGITG DOCTOR trial and the cancer evolution biobank.
Lonie JM; Brosda S; Bonazzi VF; Aoude LG; Patel K; Brown I; Sharma S; Lampe G; Addala V; Koufariotis LT; Wood S; Waddell N; Dolcetti R; Barbour AP
Front Immunol; 2023; 14():1220129. PubMed ID: 37965317
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic and immunosuppressive inflammatory cells predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma.
Göbel HH; Büttner-Herold MJ; Fuhrich N; Aigner T; Grabenbauer GG; Distel LVR
Radiother Oncol; 2020 May; 146():151-160. PubMed ID: 32169773
[TBL] [Abstract][Full Text] [Related]
10. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy.
Saigusa S; Toiyama Y; Tanaka K; Inoue Y; Mori K; Ide S; Imaoka H; Kawamura M; Mohri Y; Kusunoki M
Int J Clin Oncol; 2016 Oct; 21(5):946-952. PubMed ID: 26919982
[TBL] [Abstract][Full Text] [Related]
11. Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review.
Wang HH; Steffens EN; Kats-Ugurlu G; van Etten B; Burgerhof JGM; Hospers GAP; Plukker JTM
Ann Surg Oncol; 2024 Jan; 31(1):433-451. PubMed ID: 37777688
[TBL] [Abstract][Full Text] [Related]
12. PD-L1 expression and infiltration by CD4
Lee HJ; Shin DH; Lee YJ; Lee SJ; Hwang CS; Kim A; Park WY; Lee JH; Choi KU; Kim JY; Lee CH; Sol MY; Park SW
Histopathology; 2020 Apr; 76(5):714-721. PubMed ID: 31841221
[TBL] [Abstract][Full Text] [Related]
13. Chemoradiation-induced alteration of programmed death-ligand 1, CD8+ tumor-infiltrating lymphocytes and mucin expression in rectal cancer.
Baretti M; Zhu Q; Fu W; Meyer J; Wang H; Anders RA; Azad NS
Oncotarget; 2022; 13():907-917. PubMed ID: 35937503
[TBL] [Abstract][Full Text] [Related]
14. The Dynamic and Transient Immune Microenvironment in Locally Advanced Esophageal Adenocarcinoma Post Chemoradiation.
Kelly RJ; Zaidi AH; Smith MA; Omstead AN; Kosovec JE; Matsui D; Martin SA; DiCarlo C; Werts ED; Silverman JF; Wang DH; Jobe BA
Ann Surg; 2018 Dec; 268(6):992-999. PubMed ID: 28806299
[TBL] [Abstract][Full Text] [Related]
15. Tumor-Infiltrating CD4+ Lymphocytes Predict a Favorable Survival in Patients with Operable Esophageal Squamous Cell Carcinoma.
Chen K; Zhu Z; Zhang N; Cheng G; Zhang F; Jin J; Wu J; Ying L; Mao W; Su D
Med Sci Monit; 2017 Sep; 23():4619-4632. PubMed ID: 28949934
[TBL] [Abstract][Full Text] [Related]
16. Association between radiotherapy-induced alteration of programmed death ligand 1 and survival in patients with uterine cervical cancer undergoing preoperative radiotherapy.
Tsuchiya T; Someya M; Takada Y; Hasegawa T; Kitagawa M; Fukushima Y; Gocho T; Hori M; Nakata K; Hirohashi Y; Torigoe T; Saito T; Sakata KI
Strahlenther Onkol; 2020 Aug; 196(8):725-735. PubMed ID: 31953603
[TBL] [Abstract][Full Text] [Related]
17. Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non-small-cell lung carcinoma.
Boulle G; Velut Y; Mansuet-Lupo A; Gibault L; Blons H; Fournel L; Boni A; Cremer I; Wislez M; Duchatelle V; Trédaniel J; Hammond SA; Herbst R; Alifano M; Giraud P; Damotte D
Eur J Cancer; 2020 Aug; 135():221-229. PubMed ID: 32610210
[TBL] [Abstract][Full Text] [Related]
18. Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma.
Turkington RC; Knight LA; Blayney JK; Secrier M; Douglas R; Parkes EE; Sutton EK; Stevenson L; McManus D; Halliday S; McCavigan AM; Logan GE; Walker SM; Steele CJ; Perner J; Bornschein J; MacRae S; Miremadi A; McCarron E; McQuaid S; Arthur K; James JA; Eatock MM; O'Neill R; Noble F; Underwood TJ; Harkin DP; Salto-Tellez M; Fitzgerald RC; Kennedy RD;
Gut; 2019 Nov; 68(11):1918-1927. PubMed ID: 30852560
[TBL] [Abstract][Full Text] [Related]
19. Tumour-infiltrating lymphocytes and survival in patients with adenocarcinoma of the oesophagus.
Zingg U; Montani M; Frey DM; Dirnhofer S; Esterman AJ; Went P; Oertli D
Eur J Surg Oncol; 2010 Jul; 36(7):670-7. PubMed ID: 20510571
[TBL] [Abstract][Full Text] [Related]
20. Intratumoral budding and automated CD8-positive T-cell density in pretreatment biopsies can predict response to neoadjuvant therapy in rectal adenocarcinoma.
Farchoukh L; Hartman DJ; Ma C; Celebrezze J; Medich D; Bahary N; Frank M; Pantanowitz L; Pai RK
Mod Pathol; 2021 Jan; 34(1):171-183. PubMed ID: 32661298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
